Digoxin Pharmacology and Toxicity

Mechanism of Action (Therapeutic Effects)

• Na+/K+-ATPase inhibition: Digoxin binds irreversibly to the K+ binding site on the Na+/K+-ATPase pump on the cardiac myocyte membrane, inhibiting active sodium-potassium exchange. This increases intracellular Na+ concentration, which reduces the driving force for Na+/Ca2+ exchanger activity (operating in reverse mode), leading to increased intracellular Ca2+ storage in the sarcoplasmic reticulum and enhanced contractility (positive inotropic effect).
• Vagomimetic effects: Digoxin enhances parasympathetic (vagal) tone through enhanced acetylcholinesterase activity at muscarinic receptors and direct effects on the AV node. This prolongs AV nodal conduction time (increased PR interval) and increases the refractory period, resulting in negative chronotropic and dromotropic effects. This mechanism is responsible for rate control in atrial fibrillation and explains why digoxin's negative chronotropic effect occurs at lower doses than its positive inotropic effect.

Mechanism of Toxicity (Pathophysiology of Digoxin Toxicity)

• Excessive Na+/K+-ATPase inhibition: At supratherapeutic concentrations, pronounced Na+/K+-ATPase inhibition causes severe depletion of intracellular K+ and Na+ accumulation, paradoxically increasing automaticity. The intracellular Na+ overload reverses the Na+/Ca2+ exchanger's normal operation (now extrudes Na+ and extrudes Ca2+), resulting in intracellular Ca2+ depletion in diastole but abnormal Ca2+ release and oscillatory afterdepolarizations. These triggered activity mechanisms generate ectopic automaticity in specialized conduction tissues.
• Enhanced vagal tone exaggeration: At toxic levels, excessive AV nodal depression can precipitate severe bradycardia and complete heart block. Combined with enhanced automaticity, this creates the characteristic milieu for ectopic tachyarrhythmias in the setting of AV block (pathognomonic finding in digoxin toxicity).
• Altered myocardial repolarization: Digoxin shortens the action potential duration and QT interval (opposite of most antiarrhythmics), further enhancing automaticity. This combined with delayed afterdepolarizations (DADs) from Ca2+ overload generates multiple potential arrhythmia mechanisms.

Pharmacokinetic Risk Factors for Toxicity

• Renal insufficiency (most common predisposing factor): Digoxin undergoes 70% renal excretion unchanged; creatinine clearance <60 mL/min markedly prolongs half-life (normal 36–40 hours → up to 5–7 days in ESRD), necessitating dose reduction. Calculate loading and maintenance doses using adjusted creatinine clearance.
• Advanced age: Reduced renal function, decreased total body water, reduced muscle mass (decreased volume of distribution), and altered pharmacokinetics increase serum levels at standard doses. Elderly patients often require 50% dose reduction.
• Drug interactions: Quinidine, verapamil, amiodarone, and NSAIDs compete for renal tubular secretion or decrease hepatic metabolism, increasing digoxin levels 20–50%. Macrolide antibiotics (erythromycin, clarithromycin) alter gut flora-mediated metabolism, increasing absorption.
• Electrolyte abnormalities: Hypokalemia (most important) increases binding affinity of digoxin to Na+/K+-ATPase and lowers the toxic threshold; even mild K+ depletion substantially increases toxicity risk. Hypomagnesemia, hypocalcemia, and hypophosphatemia similarly increase susceptibility.
• Acute myocardial infarction: Increased myocardial irritability synergizes with digoxin's arrhythmogenic effects; avoid digoxin in acute MI.
• Thyroid disease: Hyperthyroidism increases metabolism and toxicity threshold (higher doses tolerated); hypothyroidism decreases clearance and increases toxicity risk.
• Cardiac conditions: Pre-existing conduction disease (Wolff-Parkinson-White syndrome, sick sinus syndrome, AV block), heart failure with preserved ejection fraction (HFPEF), and acute pulmonary embolism increase arrhythmia risk.
• Diarrhea/malabsorption: Reduced oral absorption may precipitate subtherapeutic levels, but acute GI toxicity symptoms can impair further absorption.

Intentional Toxicity (Rare)

• Suicidal ingestion (cardiotoxic drug of choice historically; now less common with modern alternatives).

Gastrointestinal Symptoms (Most Common Early Signs)

• Nausea and vomiting (common first manifestation; often dose-dependent and precedes arrhythmias)
• Anorexia and loss of appetite
• Abdominal pain, diarrhea, or constipation
• Abdominal distension and ileus (in severe toxicity)

Cardiac Arrhythmias (Most Serious Manifestations)

• Premature ventricular contractions (PVCs): Typically in patterns of bigeminy, trigeminy, or salvos; often the earliest arrhythmia
• Paroxysmal atrial tachycardia (PAT) with AV block: Classic digoxin toxicity arrhythmia; atrial rate typically 130–250 bpm with fixed high-grade AV block (pathognomonic finding distinguishing digoxin toxicity from other SVTs)
• Atrial fibrillation with a slow ventricular response (digitalis-induced AFib in patients with sinus rhythm; or slowing of pre-existing AFib beyond therapeutic rate control)
• Ventricular tachycardia or fibrillation: In severe poisoning, particularly with electrolyte abnormalities
• Bradyarrhythmias: Severe sinus bradycardia, sinus arrest, second- or third-degree AV block, even in patients without pre-existing conduction disease
• Bidirectional ventricular tachycardia: Rare but highly specific for severe digoxin toxicity (alternating QRS axis)

Central Nervous System Symptoms

• Visual disturbances: Blurred vision, yellow-green halos around lights (xanthopsia), scotomata, diplopia, photophobia (pathognomonic but rare; reported in <10% of patients)
• Headache, dizziness, vertigo
• Confusion, disorientation, delirium (especially in elderly; may be mistaken for delirium from other causes)
• Weakness, fatigue, malaise
• Psychosis, delirium, hallucinations (in severe toxicity)

Physical Examination Findings

• Arrhythmias on cardiac auscultation: Irregular rhythm, bradycardia, or noted ectopic beats
• Signs of heart failure: Rales, JVD, peripheral edema (may coexist with digoxin indication, complicating assessment)
• Vital sign abnormalities: Hypotension, bradycardia, bradypnea
• Neurologic findings: Disorientation, ataxia, weakness

Atypical Presentations

• Asymptomatic toxicity: Stable patients with elevated digoxin levels but only ECG abnormalities
• Chronic low-level toxicity: Subtle symptoms (anorexia, weakness, confusion) over weeks to months in outpatients

Serum Digoxin Concentration

• Therapeutic window: 0.8–2.0 ng/mL (0.6–1.5 ng/mL for heart failure alone; 1.5–2.0 ng/mL for AFib rate control)
• Timing of level: Draw ≥6 hours post-dose (preferably 10–14 hours post-oral dosing) to allow distribution phase completion; earlier draws will be falsely elevated
• Interpretation: Levels >2.0 ng/mL suggest toxicity, but clinical toxicity can occur at therapeutic or even subtherapeutic levels if electrolytes are abnormal. Conversely, some patients tolerate levels up to 3–4 ng/mL without toxicity. Clinical judgment must integrate symptoms, ECG findings, and electrolytes rather than relying solely on serum level.
• False elevation: Elderly patients, renal disease, and pregnancy can have analytically elevated levels due to digoxin-like immunoreactive substances (DLIS) from endogenous sources; mass spectrometry clarifies if needed.

Electrolytes and Metabolic Panel

• Serum potassium (critical for toxicity risk assessment): Hypokalemia (<3.5 mEq/L) substantially increases toxicity risk; aim for K+ >4.0 mEq/L in patients on digoxin
• Serum magnesium: Hypomagnesemia (<1.7 mg/dL) increases toxicity; replicate Mg2+ to K+ >4.0 and Mg2+ >2.0
• Serum calcium: Hypercalcemia increases toxicity risk
• Renal function (BUN, creatinine, eGFR): Determine dose adjustments and expected clearance
• Acid-base status: Alkalosis increases toxicity (alkalemia shifts K+ intracellularly, effectively lowering serum K+)

Electrocardiogram (ECG) — Most Important Diagnostic Tool

• Sagging "ST segment depression with upward convexity" ("digoxin effect" or "digoxin strain"): Characteristic appearance even at therapeutic levels; represents repolarization abnormality and is not itself evidence of toxicity but indicates patient is receiving digoxin
• PR interval prolongation: AV nodal delay from vagomimetic effects; mild prolongation expected therapeutically
• QT shortening: Characteristic of digoxin effect
• AV block: First-degree (prolonged PR), second-degree (Wenckebach or Mobitz II), or third-degree block; indicates excess vagal tone
• Atrial arrhythmias: Premature atrial contractions (PACs), atrial fibrillation, atrial flutter, or PAT (especially with AV block)
• Ventricular arrhythmias: PVCs (bigeminy most common), ventricular tachycardia, bidirectional VT (pathognomonic)
• Sinus bradycardia or arrest: From excessive AV nodal and sinus node depression
• Junctional rhythms: AV nodal automaticity from toxicity
• Pattern recognition: Look for a "triplet" pattern (PVC sandwiched between normal beats), frequent multifocal PVCs, PAT with high-degree AV block, or bidirectional VT to raise suspicion

Diagnosis of Toxicity: Integrated Approach

• Clinical diagnosis: Constellation of GI symptoms (nausea, anorexia, vomiting), cardiac arrhythmias (especially PAT with AV block, PVCs, bigeminy), CNS symptoms (visual disturbances, confusion), plus supportive ECG findings and elevated serum digoxin level (>2.0 ng/mL) or electrolyte abnormalities (hypokalemia, hypomagnesemia) in the correct clinical context
• Exclusion of mimics: Rule out other causes of arrhythmia (MI, ischemia, thyrotoxicosis, electrolyte abnormalities from non-digoxin causes, primary conduction disease)

Management of Chronic Digoxin Use (Prevention of Toxicity)

• Appropriate dosing: Use reduced doses in renal insufficiency; typical loading dose 8–12 mcg/kg (IV or oral), maintenance 2–6 mcg/kg/day divided daily (renally adjusted). Elderly patients typically require 50% dose reduction.
• Monitor serum levels regularly: Initial level at 1–2 weeks post-initiation, then annually or after dose changes; more frequent monitoring in renal disease or with new drug interactions
• Maintain electrolytes: Regular K+, Mg2+, Ca2+ monitoring; replicate K+ to >4.0 mEq/L and Mg2+ to >2.0 mg/dL
• Avoid triggering factors: NSAIDs (contraindicated), confirm no CYP3A4 inhibitors (amiodarone, verapamil, quinidine)
• Renal function reassessment: Recalculate clearance every 6–12 months in elderly or in patients with baseline renal disease

Management of Digoxin Toxicity

Mild to Moderate Toxicity (GI symptoms, isolated PVCs, minor arrhythmias)

• Discontinue digoxin immediately
• Supportive care: NPO status temporarily if vomiting; antiemetics if needed (metoclopramide safe)
• Electrolyte repletion: IV K+ to achieve 4.0–5.0 mEq/L (give cautiously if serum K+ already elevated or with pre-existing renal disease or AV block; do not give K+ if AV block present as it may precipitate complete heart block); IV Mg2+ sulfate to achieve Mg2+ >2.0 mg/dL
• Observation and monitoring: Serial ECGs and electrolytes; most mild-moderate cases resolve within 24–48 hours if digoxin withheld
• Correction of precipitants: Address hypokalemia, hypomagnesemia, hypercalcemia, acidosis, thyroid dysfunction, dehydration

Moderate to Severe Toxicity (Dangerous arrhythmias, high-degree AV block, hemodynamic instability)

• Discontinue digoxin immediately
• Aggressive electrolyte repletion: IV K+ to target 4.5–5.0 mEq/L if initial K+ normal or low (use caution with ECG monitoring in presence of AV block; may worsen block acutely before improving ectopy)
• Antiarrhythmic therapy:
• Lidocaine (first-line for PVCs/VT): Bolus 1–1.5 mg/kg IV, then infusion 1–4 mg/min; works rapidly and is safe in renal disease
• Phenytoin (fosphenytoin): Bolus 50–100 mg IV over 5–10 min, then 50–100 mg q5–10 min up to 15 mg/kg; excellent choice for ventricular ectopy in digoxin toxicity; enhances AV conduction (helpful in bradyarrhythmias unlike other antiarrhythmics)
• Avoid Class I antiarrhythmics (quinidine, procainamide) in early toxicity as they increase digoxin levels and can worsen toxicity
• Avoid verapamil (enhances AV block) if high-degree block present
• Avoid amiodarone in acute toxicity (increases digoxin levels)
• Treatment of bradyarrhythmias:
• Atropine (0.5–1 mg IV q3–5 min, max 3 mg): Blocks vagal effects on AV node and sinus node; first-line for bradycardia and high-degree AV block from digoxin toxicity
• Temporary pacing: If atropine fails to improve symptomatic bradycardia or high-degree block (place transcut

Cardiac (dose-limiting)

• Proarrhythmia: Delayed afterdepolarizations from Ca2+ overload plus vagally mediated AV nodal block produce the signature combination of enhanced automaticity with impaired conduction — atrial tachycardia with block, junctional tachycardia, frequent PVCs/bigeminy, and bidirectional ventricular tachycardia. Any new arrhythmia in a patient on digoxin should be presumed drug-related until proven otherwise.
• Bradyarrhythmias: Sinus arrest and high-grade AV block, especially when combined with beta blockers, non-dihydropyridine calcium channel blockers, or amiodarone.

Non-cardiac

• Gastrointestinal: Nausea, anorexia, vomiting — mediated centrally at the chemoreceptor trigger zone as well as locally, so they occur with IV as well as oral dosing.
• Visual: Xanthopsia (yellow-green halos) and blurring, from glycoside inhibition of Na+/K+-ATPase in retinal photoreceptors.
• Neuropsychiatric: Confusion and delirium, disproportionately in the elderly.
• Endocrine: Gynecomastia with chronic use, attributed to the steroid-like glycoside nucleus.
• Mesenteric ischemia: Rare; splanchnic vasoconstriction from the same Ca2+-loading mechanism.

Contraindications/cautions

• Pre-excited atrial fibrillation (WPW): Digoxin shortens accessory-pathway refractoriness and can accelerate conduction to ventricular fibrillation — the ACC/AHA/ACCP/HRS atrial fibrillation guideline directs AV-nodal blockers away from pre-excited AF.
• High-grade AV block without a pacemaker, hypertrophic obstructive cardiomyopathy, and infiltrative/amyloid cardiomyopathy (heightened sensitivity).

Reversal

• Digoxin-specific antibody fragments (DigiFab): The only true antidote; indicated for life-threatening arrhythmias, refractory bradycardia, hemodynamic instability, or hyperkalemia from acute poisoning. After administration, total serum digoxin assays are uninterpretable (bound drug is measured).
• Hemodialysis is ineffective because of the large volume of distribution and extensive tissue binding.

• Two ECG buzzwords: Atrial tachycardia with AV block and bidirectional ventricular tachycardia are the stem's way of naming digoxin toxicity. Bidirectional VT has one major distractor — catecholaminergic polymorphic VT in a young patient with exercise-induced syncope.
• "Digoxin effect" is not toxicity: The scooped/sagging ST depression with shortened QT appears at therapeutic levels. Do not choose "hold digoxin" for this finding alone.
• Potassium tells you acute vs chronic: Acute overdose blocks Na+/K+-ATPase globally and causes hyperkalemia, which correlates with severity and is itself an indication for antibody fragments. Chronic toxicity in a diuretic-treated elderly patient is typically hypokalemic, and hypokalemia enhances digoxin binding to the pump.
• Single best next step in an unstable patient: Digoxin-specific antibody fragments (DigiFab) — not lidocaine, not pacing, not dialysis. Levels drawn afterward are uninterpretable.
• Do not give IV calcium for digoxin-associated hyperkalemia; the classic teaching is that added Ca2+ worsens the existing intracellular calcium overload. Treat the hyperkalemia by reversing the drug.
• The one association examiners love: A new drug that raises digoxin levels — amiodarone, verapamil, quinidine, or a macrolide — plus worsening renal function in an elderly patient, presenting as anorexia, confusion, and yellow-green halos.
• Know where digoxin sits in therapy: Per the AHA/ACC/HFSA heart failure guideline, digoxin may reduce hospitalizations but not mortality in HFrEF, and it is an add-on only. Guideline-directed therapy remains four classes — ARNI (or ACEI/ARB), beta blocker, MRA, and SGLT2 inhibitor. Per the ACC/AHA/ACCP/HRS atrial fibrillation guideline, digoxin is adjunctive rate control, favored when hypotension limits beta blockers, and is contraindicated in pre-excited AF.
• Timing trap: A level drawn before distribution completes (roughly within 6 hours of a dose) is falsely high — repeat rather than treat.